Purchase this article with an account.
Alessandra Sborgia, Homayoun Tabandeh, Lorenza Ciracì, Cesare Mariotti, Claudio Furino, Francesco Boscia; Endophthalmitis After Intravitreal Injections: In-office Setting Vs Operating Room Setting. Invest. Ophthalmol. Vis. Sci. 2012;53(14):1696.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report on the occurrence of endophthalmitis following intravitreal injections (IVI) in two different settings: in-office and in operating room.
Retrospective review of all patients who underwent intravitreal injections in two retina practices. Group (A) underwent intravitreal injection in the examination room in office setting and Group (B) underwent intravitreal injection in the operating room.
Group( A): A total of 5687 IVI performed including 1895 ranibizumab, 3494 bevacizumab, and 298 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (3877 eyes), diabetic macular edema (999), retinal vein occlusion (722), and miscellaneous diagnosis (89) eyes. Group( B): A total of 3063 IVI performed including683 ranibizumab, 2364 bevacizumab, and 16 triamcinolone acetonide. The diagnosis included neovascular age-related macular degeneration (1836 eyes), diabetic macular edema (771), retinal vein occlusion (189), and miscellaneous diagnosis (267) eyes. In group (A) two (0.035%) cases of endophthalmitis occurred in 5687 intravitreal injections. In group (B) two (0.065%) cases of endophthalmitis occurred in 3063 intravitreal injections.
The rate of endophthalmitis after intravitreal injections is low whether the procedure is performed in the office or in the operating room setting. The findings have implications in terms of the patient convenience, efficiency, and cost of administrating these treatments
This PDF is available to Subscribers Only